14-day Premium Trial Subscription Try For FreeTry Free

TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates

01:45pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
TG Therapeutics, Inc. (TGTX) CEO Michael Weiss on Q4 2021 Results - Earnings Call Transcript
TG Therapeutics press release (TGTX): Q4 GAAP EPS of -$0.70 misses by $0.08.Revenue of $2.32M (+5700.0% Y/Y) beats by $0.08M.
Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -12.90% and 76.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics Q4 2021 Earnings Preview

05:12pm, Monday, 28'th Feb 2022 Seeking Alpha
TG Therapeutics (NASDAQ:TGTX) is scheduled to announce Q4 esults on Tuesday, Mar. 1, before market open.Consensus EPS estimate is -$0.68 and consensus revenue estimate is $2.4M
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACT

AdaptHealth Corp. (AHCO) Q4 Earnings Miss Estimates

01:05pm, Thursday, 24'th Feb 2022 Zacks Investment Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -62.50% and 1.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET Conference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials eva
TGTX is trading like a junk stock after the FDA announced that it is investigating umbralisib in CLL over safety concerns. However, people tend to forget, ublituximab for MS is the heart of TGTX.

TG Therapeutics slips on concerns over FDA probe on cancer medicine

03:22pm, Thursday, 03'rd Feb 2022 Seeking Alpha
TG Therapeutics <> is trading lower after the FDA announced an ongoing investigation over the increased risk of death related to the companys cancer medicine

TG Therapeutics (TGTX) Moves 17.7% Higher: Will This Strength Last?

07:04am, Monday, 31'st Jan 2022 Zacks Investment Research
TG Therapeutics (TGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE